Tukysa (tucatinib) reimbursed in British Columbia for the treatment of patients with advanced or metastatic HER2 positive breast cancer

6 December 2022 - BC is the third province to add Tukysa to its provincial dormulary. ...

Read more →

B.C. family grateful for expanded funding to cystic fibrosis drug, but questions why it took so long

7 September 2022 - B.C. is last Canadian jurisdiction to fund Trikafta for patients with cystic fibrosis age 6 to 11. ...

Read more →

British Colombia expands children’s access to ‘transformational’ cystic fibrosis drug

7 September 2022 - A week after a B.C. family went public with its plea for a life-changing drug for ...

Read more →

Funding for lifesaving drug denied by B.C. health authority as couple struggles to fund their portion

7 August 2022 - Entrectinib, a targeted drug that had shown positive results in tumours that had the same gene expression, ...

Read more →

Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, join a growing list of provinces providing public drug plan reimbursement for Teva Canada’s Ajovy (fremanezumab), for the preventive treatment of migraine in adults

17 May 2022 - Teva Canada welcomes the recently announced public formulary coverage for Ajovy (fremanezumab) by Ontario, British Columbia, ...

Read more →

Baqsimi (nasal glucagon), rescue treatment for severe hypoglycaemia now covered in British Colombia, Alberta & Saskatchewan

27 April 2022 - Lilly Canada is pleased to announce that as of 5 April 2022, Baqsimi (glucagon nasal powder) ...

Read more →

Astellas announces reimbursement for Xospata (gilteritinib) in most provinces for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation

21 April 2022 - Having access to an additional treatment option offers hope for Canadian adult AML patients with relapsed ...

Read more →

AbbVie announces provincial reimbursement for Venclexta (venetoclax) with obinutuzumab for patients with previously untreated chronic lymphocytic leukaemia in Alberta, Saskatchewan, British Columbia and Manitoba

24 February 2022 - AbbVie announced today that Alberta, Saskatchewan, British Columbia, and Manitoba now reimburse Venclexta (venetoclax) in combination ...

Read more →

Drug funded for people with spinal muscular atrophy

15 February 2022 - The provincial government is covering costs for risdiplam, or Evrysdi, the medication used to treat a severe ...

Read more →

B.C. woman petitions province to cover cost of 'life-changing' migraine medication

29 March 2021 - Christina Sall says Aimovig is the only drug that helps her, but it costs her more than ...

Read more →

B.C. family nearing finish in race to raise $2.8 million to treat baby's rare disease

8 August 2020 - Parents hope funds will pay for expensive therapy not approved in Canada for type 1 spinal muscular ...

Read more →

B.C. eye-injection program ‘clouded in secrecy’

28 January 2020 - Two dozen ophthalmologists are accusing the B.C. government of failing to properly investigate concerns that a ...

Read more →

B.C. funding decision on pricey drug leaves teen with rare disease facing 'scary' future

13 January 2020 - Miles Ambridge just misses cut-off age to access Spinraza, a potentially life-changing treatment. ...

Read more →

B.C. wants federal health funding lift before national pharmacare program

3 December 2019 - B.C. wants more money from Ottawa for health care before a national pharmacare program is created, ...

Read more →

Erosion of physician and patient treatment choice continues - Alliance for Safe Biologic Medicines raises concerns for patients as British Columbia expands biologics forced switching policy

10 September 2019 - On 5 September, the Government of British Columbia announced that it would be forcibly switching 1,700 patients ...

Read more →